6 articles to expand your understanding of syndromic testing
Gain insight into how syndromic testing can improve pathogen detection, lead to better-informed treatment plans, and aid antimicrobial stewardship
9 Aug 2021
Syndromic testing is a powerful approach that enables the simultaneous detection of multiple pathogens in one single test, saving valuable diagnostic time when compared to traditional testing methods, an attribute that has proved vital during the COVID-19 pandemic.
Here, we’ve pulled together six exclusive articles to boost your understanding of syndromic testing and demonstrate the positive impacts this innovative approach is having on the diagnosis of respiratory infections, CNS inflammation, gastrointestinal pathogens, and more. Plus, learn how the use of syndromic testing panels can promote antimicrobial stewardship and improve resistance.
Syndromic testing: A powerful approach for simultaneous pathogen detection
Our introductory article outlines the fundamental principles and processes of syndromic testing, with a case study example, helping you understand its key benefits. Plus, discover a comprehensive overview of the syndromic panel portfolio offered by BioFire Diagnostics.
The role of syndromic testing in the era of COVID-19
In this new age of viral infection, learn more about the pathogenic trends observed during the COVID-19 pandemic and about the important role syndromic testing has played.
Antimicrobial stewardship: Helping combat the spread of antimicrobial resistance
Gain insights into why syndromic testing panels are empowering prescribers, identifying potential resistance mechanisms, and aiding antimicrobial stewardship.
Pneumonia diagnosis & management: Is this the new standard of care?
Clinicians face diagnostic issues with culture-based testing methods when identifying and treating pneumonia. Discover how syndromic testing could improve antimicrobial stewardship and become the new standard of care.
Achieving better clinical outcomes for gastrointestinal pediatric patients
Efficient diagnosis of gastrointestinal pathogens is not just beneficial for patient treatment, it could also help in the identification of a potential outbreak. Find out how a syndromic testing panel can solve the pitfalls of traditional testing.
CNS inflammation: Reducing time to optimal therapy with syndromic testing
The presentation of infections such as meningitis or encephalitis is often nonspecific and can be problematic to diagnose effectively. Find out how syndromic testing can overcome some of these challenges and improve patient management.
Learn more about the BioFire® FilmArray® System panels:
- BioFire® Respiratory 2.1 Panel (EUA)*>>
Test for the usual respiratory suspects, including Influenza and SARS-CoV-2*. - BioFire® FilmArray® Pneumonia Panel >>
Help distinguish between colonizing and infection-causing bacteria with semi-quantitative results and promote antimicrobial stewardship. - BioFire® FilmArray® Meningitis/Encephalitis Panel >>
Distinguish between bacterial and viral meningitis and optimize life-saving therapy. - BioFire® FilmArray® Gastrointestinal Panel >>
Test for the most common pathogens associated with gastroenteritis. - BioFire® Blood Culture Identification 2 Panel >>
Test for a broad group of pathogens and antimicrobial resistance markers to help improve the management of patients with bloodstream infections.
*About Emergency Use Authorization:
- This test has not been FDA cleared or approved.
- This test has been authorized by FDA under an EUA for use by authorized laboratories.
- This test has been authorized only for the detection and differentiation of nucleic acid of SARS-CoV-2 from multiple respiratory viral and bacterial organisms.
- This test is only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of in vitro diagnostics tests for detection and/or diagnosis of COVID-19 under Section 564(b)(1) of the Act, 21 U.S.C. § 360bbb-3(b)(1), unless the authorization is terminated or revoked sooner
